MEDOPP556 The PONTIAC Study
A randomized phase II Study to evaluate the safety and efficacy of trastuzumab deruxtecan versus CDK4/6 inhibitor-based endocrine therapy as first-line therapy of HR-positive and HER2-low/ultralow advanced breast cancer patients classified as non-luminal subtype according to gene expression profiling (PONTIAC Study)
Detalhes
Destaques